Hepatology

MASLD and MASH: Steatotic liver disease joins the deadly quartet
Risheng Xu, DO, Nicola Abate, MD, Rise Stribling, MD and Richard Su, PhD
- Cleveland Clinic Journal of Medicine September 2026, 93 (9) 551-559;
- DOI: https://doi.org/10.3949/ccjm.93a.25117
- Like obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus, metabolic dysfunction–associated steatotic liver disease is ubiquitous; however, awareness of it remains low.
Letter: Beyond histologic improvement in MASH
Mahwish Najam, MBBS, Janita Zahir, Khadija Tul Kubra and Abeera Saleem Mughal
- Cleveland Clinic Journal of Medicine July 2026, 93 (7) 380-381;
- DOI: https://doi.org/10.3949/ccjm.93c.07003
In Reply: Beyond histologic improvement in MASH
Leandro Sierra, MD, Lily Liu, MD, Akash Khurana, MD, Roma Patel, MD, Arjun Chatterjee, MD, Stephen Firkins, MD and Roberto Simons-Linares, MD
- Cleveland Clinic Journal of Medicine July 2026, 93 (7) 381;
- DOI: https://doi.org/10.3949/ccjm.93c.07004
What screening approach could improve early detection of ‘at-risk’ metabolic dysfunction–associated steatohepatitis in my patients?
Zehra Naseem, MD, Yael Mauer, MD, MPH and Sobia Laique, MD
- Cleveland Clinic Journal of Medicine July 2026, 93 (7) 397-401;
- DOI: https://doi.org/10.3949/ccjm.93a.26013
- Screening for MASH follows a stepwise, sequential approach, beginning with calculation of the fibrosis-4 index
Reversing fibrosis in metabolic dysfunction–associated steatohepatitis—beyond telling patients to lose weight
Leandro Sierra, MD, Lily Liu, MD, Akash Khurana, MD, Roma Patel, MD, Arjun Chatterjee, MD, Stephen Firkins, MD and Roberto Simons-Linares, MD
- Cleveland Clinic Journal of Medicine May 2026, 93 (5) 279-286;
- DOI: https://doi.org/10.3949/ccjm.93a.25082
- Weight loss of at least 10% is associated with fibrosis regression in most patients, but losing this amount of weight and keeping it off is challenging, making pharmacologic and procedural interventions essential tools in clinical practice.
Unexplained liver injury: Searching for the cause
Mohamed Eldib, MD, William D. Carey, MD and Blazenka Skugor, MD
- Cleveland Clinic Journal of Medicine May 2026, 93 (5) 267-272;
- DOI: https://doi.org/10.3949/ccjm.93a.25099
- The patient presented with persistent low back pain, nausea, poor appetite, and an unintentional weight loss of more than 30 lb over the previous 6 weeks.
‘Even when the wound is healed, the scar remains’
Brian F. Mandell, MD, PhD
- Cleveland Clinic Journal of Medicine May 2026, 93 (5) 255-256;
- DOI: https://doi.org/10.3949/ccjm.93b.05026
- Persistent or repetitive inflammatory or ischemic insults to internal organs may lead to progressive scarring that culminates in organ failure.
Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily
Pranay Nadella, MD, MPhil, Esperance Schaefer, MD, MPH and Clare Landefeld, MD, MS
- Cleveland Clinic Journal of Medicine February 2026, 93 (2) 88-93;
- DOI: https://doi.org/10.3949/ccjm.93a.25045
- Clinicians in the primary care setting can identify patients with heavy alcohol use and alcohol-related liver disease before they develop advanced liver damage.
Does my patient with acute variceal hemorrhage need a transjugular intrahepatic portosystemic shunt?
Mahnur Haider, MD, Indira Bhavsar-Burke, MD, Robert S. O’Shea, MD, MSCE and Christina C. Lindenmeyer, MD
- Cleveland Clinic Journal of Medicine July 2024, 91 (7) 409-413;
- DOI: https://doi.org/10.3949/ccjm.91a.24014
- Placement of a transjugular intrahepatic portosystemic shunt can be used as salvage therapy to control bleeding when endoscopic management fails and as a means of secondary prophylaxis in select patients.
What are the management considerations for venous thromboembolic events in patients with cirrhosis?
Marie M. Plante, MD, BSN, RN, Emily B. Wolf, MD and Razvan M. Chirila, MD
- Cleveland Clinic Journal of Medicine February 2024, 91 (2) 86-88;
- DOI: https://doi.org/10.3949/ccjm.91a.23045
- The authors review the current evidence on venous thromboembolic event (VTE) risk prediction in patients with cirrhosis, as well as VTE prophylaxis and anticoagulant therapy.